MedTrace Logo

Switching From Protease Inhibitor/Ritonavir to Generic Single Tablet Regimen of Tenofovir Alafenamide/Emtricitibine/Dolutegravir

NCT03727152 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 170

Last updated 2024-02-28

No results posted yet for this study

Summary

This is a phase III, multicenter, open-label, single-arm study of 190 virologically suppressed HIV-infected adults

Conditions

Interventions

DRUG

generic single tablet TAF/FTC/DTG

HIV-infected adults who are virologically suppressed and on protease inhibitor/ritonavir are switched to generic single tablet regimen of tenofovir alafenamide/emtricitibine/dolutegravir

Sponsors & Collaborators

  • Faculty of Medical Sciences, Radboud University of Medical Center

    collaborator UNKNOWN

  • Department of Pharmaceutical care, Faculty of Pharmacy, Chiang Mai University

    collaborator UNKNOWN

  • Police General Hospital

    collaborator OTHER

  • The HIV Netherlands Australia Thailand Research Collaboration

    lead OTHER

Principal Investigators

  • Sivaporn Gatechompol, MD · The HIV Netherlands Australia Thailand Research Collaboration

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-01
Primary Completion
2023-04-04
Completion
2023-04-04

Countries

  • Thailand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03727152 on ClinicalTrials.gov